The longitudinal physiology layer for drug development and clinical care

Measuring how disease and treatment change the heart and lungs.

Eupnoos is a deeptech company developing cardiopulmonary biomarkers for AI-enabled drug discovery and development, clinical trials and everyday care.

We are building a longitudinal physiological data layer that sits alongside molecular, imaging and clinical data—adding repeated measurements of how patients change through disease, treatment and recovery.

Our proprietary recording technology and computational platform support a connected ambition: discover meaningful biomarkers, develop them into clinical trial measurements, and validate their use in routine screening and monitoring.

Vita captures. SounDx-FM analyses. INFER supports interpretation.

For drug development For clinical care Explore our platform
From research to care

From understanding treatment response to supporting everyday decisions.

Longitudinal physiology has a role throughout the journey from research to care.

SettingWhat we are developing towards
AI-enabled drug discovery and developmentPhysiological data that complement other biological evidence, helping researchers investigate patient differences and treatment-response patterns
Clinical trialsCandidate biomarkers and measurement endpoints for studying cardiopulmonary change during treatment
Standard clinical careValidated screening and monitoring tools that support further assessment, clinical review and continuity between hospital and home

Our initial research programmes build the evidence for these applications. Each clinical use requires its own validation and applicable regulatory authorisation.

The same scientific foundation, developed for different decisions—from evaluating a therapy to deciding when a patient needs further assessment.

Where we work

Where biology becomes measurable physiology.

Disease and treatment act across biological scales—from molecules and cells to tissues, organs and patient outcomes.

Eupnoos works at the organ physiology and biophysics layer, investigating breath acoustics as a source of information about cardiopulmonary function.

Biological scaleWhat it describes
Molecules and cellsBiological pathways, drug activity and cellular responses
Tissues and organsChanges in tissue structure and organ function
Physiological measurement — our focusMeasurable characteristics of cardiopulmonary function
Clinical outcomesSymptoms, functional capacity, deterioration and recovery

We develop measurements intended to connect biological understanding with the patient’s experience of disease and treatment.

Our science

From acoustic data to clinically meaningful biomarkers.

Breath contains information about physiological function. Our research investigates how that information can become a reliable, clinically useful measurement.

Eupnoos brings together proprietary recording technology, computational modelling and clinical research to develop cardiopulmonary biomarkers. We call our field of work audiomics: the study of acoustic information for physiological measurement.

Our programmes evaluate candidate measurements alongside established clinical assessments, with a focus on reliability, biological relevance and a clearly defined use.

The goal is to develop biomarkers grounded in an understanding of disease mechanisms and supported by evidence in the populations where they will be used.

Educational visualisation of the airway tree and air sacs
Our platform

Three connected modules. One clinical purpose.

Vita breath recorder in use
Capture

Vita

Purpose-built recording for physiological measurement.

Reliable measurements begin with reliable recordings.

Vita combines our proprietary breath-recording device with smartphone software. We developed it to support consistent data collection while keeping measurement practical for patients and clinical teams.

A dedicated recording system gives us greater control over data acquisition and provides a common foundation for our biomarker programmes.

Vita is designed to support repeated recordings across research, clinical and home settings.

Proprietary recording technology. Practical measurement. Built for repeated use.

Educational cross-section of an airway
Analysis

SounDx-FM

Our foundation model programme.

SounDx-FM supports the analysis of respiratory acoustic data and the development of candidate cardiopulmonary biomarkers.

It is part of our investment in proprietary computational technology for biomarker discovery and measurement.

Educational visualisation of heart and lungs
Interpretation

INFER

Support for clinical interpretation.

INFER is being developed to support interpretation of physiological change within a patient’s clinical context.

Its purpose is to help connect a measurement with the clinical question being investigated.

What we are developing

Measurements of change, grounded in clinical purpose.

Our development programmes connect three elements:

ElementPurpose
A physiological measurementQuantify a defined characteristic and assess how it changes over time
A candidate clinical biomarkerEstablish whether that measurement meaningfully reflects a biological or clinical process
A measurement endpointDefine how the measurement will be used to answer a specific question within a clinical study

A mechanistic model provides the scientific framework for investigating what a change may represent. Clinical validation establishes whether the measurement is useful for its intended application.

Each programme is developed around a defined population, setting and context of use.

Educational comparison of lung tissue structure
Our research focus

Cardiopulmonary science with applications across disease and treatment.

Our research spans airway disease, interstitial lung disease and heart failure.

Across these areas, we evaluate candidate measurements for screening, treatment monitoring and clinical research. A particular focus is cardiopulmonary change during therapies that may affect the heart or lungs.

We work with clinical collaborators to identify meaningful questions and build the evidence needed to translate promising measurements into practical applications.

From discovery to standard clinical care

Connect a physiological measurement to a clear next step.

Our ambition extends from biomarker discovery to everyday care.

With appropriate validation, a measurement developed in clinical research can support screening and monitoring in routine practice. Each application must answer a practical question: who needs further assessment, whose condition is changing, and when should a clinician review their care?

Screening and referral

In primary care and community settings, our goal is an accessible first assessment that helps identify people who may need further cardiopulmonary investigation.

Results would support a defined referral pathway alongside symptoms, medical history and clinical judgement.

Monitoring established disease

For people living with respiratory disease or heart failure, repeated measurements could provide additional information about change between appointments.

Our development focus is to establish which changes are clinically meaningful and how they should inform review.

Monitoring during treatment

For patients receiving therapies that may affect the heart or lungs, measurements between visits could support closer observation of cardiopulmonary health.

We are developing this approach to complement established investigations and clinical assessment.

Continuity between hospital and home

Portable measurement creates an opportunity to follow patients across care settings—from hospital assessment to recovery and monitoring at home.

Our goal is to provide a consistent measurement history that helps clinical teams understand a patient’s trajectory.

A practical pathway into care

Record Complete a breath recording using Vita
Measure Produce the measurement validated for the intended application
Review Consider the result alongside other clinical information
Act Follow an agreed pathway for further assessment or continued monitoring

We develop towards clinical adoption through prospective validation, workflow evaluation and the applicable regulatory pathway.

Our evidence

Grounded in clinical research. Advancing towards biomarkers of change.

Our research spans airway disease, heart failure and interstitial lung disease, with clinical studies across the UK, Europe and Asia.

Working with clinical and academic collaborators, we evaluate breath acoustics alongside established assessments of lung function, imaging and blood biomarkers.

Building on our screening research, our next phase focuses on longitudinal change: understanding how acoustic measurements relate to disease progression, treatment response and cardiopulmonary adverse events.

Presented at

American Thoracic Society (ATS) — Respiratory Innovation Summit (RIS) 2025 European Society of Cardiology (ESC) — Heart Failure 2026
Axial chest CT, anonymised clinical image
Awards and recognition

Recognised for advancing cardiopulmonary innovation.

2024

Serge Weinberg Trophy

Awarded by Sanofi Foundation S, Future4Care and 21st by CentraleSupélec for our work in airways disease.

2025

Boehringer Ingelheim Call4StartUps

Gold recognition.

2026

MedTech Innovator

Selected for the cohort through the American Heart Association track.

2026

DayOne Accelerator

Selected for the Basel programme supporting innovation in healthcare and pharmaceutical research and development.

Our team

Expertise across technology, artificial intelligence and clinical medicine.

Eupnoos brings together experience in technology development, computational science and cardiopulmonary research.

AG

Arshia Gratiot

Founder and Chief Executive Officer

Technology leader with more than 15 years’ experience, including Nokia and Microsoft. Founded Eupnoos to make cardiopulmonary measurement more accessible.

DK

Dr Deepak Kotak

Co-founder and Chief Medical Officer

An intensive care physician, Deepak brings clinical expertise in the care of critically ill patients to Eupnoos’s technology development and clinical translation.

YR

Dr Yordan Raykov

Chief Technology Officer

Brings expertise in machine learning, probabilistic modelling and causal inference to Eupnoos’s technology development.

AS

Professor Antonius Schneider

Chief Scientific Officer

Contributes clinical research expertise to the scientific development and evaluation of cardiopulmonary measurements.

YF

Dr Yiyun Fan

Physics and Forward Modelling

Develops the physical models of breath acoustics that underpin Eupnoos’s approach to measurement.

MS

Dr Mahdi Shaban

Machine Learning

Develops computational methods for the analysis of respiratory acoustic data.

CS

Chas Sheppard

Engineering

Develops the recording technology and software supporting Eupnoos’s measurement platform.

Clinical collaborators

Professor Joanne Porter

Interstitial lung disease.

Dr Adam Pennycuick

Oncology; treatment-related pulmonary complications.

Professor Marisa Crespo-Leiro

Heart failure and cardiology.

Partnership

Develop the next measurement of cardiopulmonary change.

Partner with Eupnoos to connect a clinical question with a new approach to physiological measurement.

We work with pharmaceutical teams, clinical investigators and technology partners to advance candidate biomarkers from discovery through clinical evaluation and translation.

Start a collaboration Discuss your clinical programme